Using a monoclonal antibody directed against NT on ovarian human cancer cells inoculated in mice, Liu et al. showed that a reduction in NT/NTR1 activation improved the response to the platinum salt therapy as it decreased tumor size when cisplatin was combined with an NT antibody. The gene discussed is NTSR1; the disease is neoplasm.